Earnings Scheduled For August 11, 2021
Companies Reporting Before The Bell
• Wireless Telecom Group (AMEX:WTT) is likely to report earnings for its second quarter.
Analyzing Compass Pathways’s Unusual Options Activity
Shares of Compass Pathways (NASDAQ:CMPS) saw some unusual options activity on Tuesday. Following the unusual option alert, the stock price moved down to $32.52.
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Psilocybin Alpha.
In just a couple of years, psychedelics took the world of investing by storm.
Field Trip Health Heads To The Nasdaq As Wall Street Opens Up To “Psychedelics Renaissance”
Excitement around psychedelics grows as major U.S. exchanges make room for more companies in the sector.
Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies
Irish 5-MeO-DMT Company GH Research Debuts On Nasdaq
GH Research, a Dublin-based company studying the potential of 5-MeO-DMT for the treatment of psychiatric and neurological disorders, is now listing its stock on the Nasdaq under the symbol “GHRS.”
Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More
Institutional analysts are taking a liking to the industry of medicinal psychedelics. This week, investment bank Maxim Group initiated coverage of companies in the psychedelics space, giving a bullish Buy rating to all 10.
Compass Pathways Completes Target Administration Of Psilocybin Therapy In World’s Largest Study
Compass Pathways (Nasdaq: CMPS), a biotech company in the psychedelics space, announced it has completed a key milestone on its path to obtaining FDA approval for psilocybin in the treatment of depression.
Pandemic Fallout: 6 Mental Health Stocks To Watch
One of the most devastating long-term impacts of the COVID-19 pandemic may be the toll it has taken on people’s mental health. The next global health crisis may be related to mental health issues such as anxiety and depression, and companies that are focused on mental health could be well-positioned to capitalize on the opportunity.
Maxim Group Initiates Coverage On Compass Pathways with Buy Rating, Announces Price Target of $70
Maxim Group analyst Jason McCarthy initiates coverage on Compass Pathways (NASDAQ:CMPS) with a Buy rating and announces Price Target of $70.
Peter Thiel-backed Psychedelics Company Rings Nasdaq Bell: Atai Life Sciences Goes Public
Atai Life Sciences (NASDAQ: ATAI), a biotech company in the psychedelic space, had its Nasdaq debut on Friday.